Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2012, Pages 355-362

  Schmouder, Robert ^a   Hariry, Sam ^b   David, Olivier J ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Absolute lymphocyte count; Cardiac function; Fingolimod; Heart rate; Pulmonary function

Indexed keywords

FINGOLIMOD; PLACEBO;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FUNCTION; HEART OUTPUT; HEART PALPITATION; HEART RATE; HEART RHYTHM; HEART STROKE VOLUME; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION; LYMPHOCYTE COUNT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE;

ADULT; CARDIAC OUTPUT; DOUBLE-BLIND METHOD; FEMALE; HEART; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROPYLENE GLYCOLS; RESPIRATORY FUNCTION TESTS; SPHINGOSINE; STROKE VOLUME; VASCULAR RESISTANCE;

EID: 84860284278     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1146-9     Document Type: Article

References (17)

1. Brinkmann V (2009) FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158(5):1173-1182
2. Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33(2):91-101
3. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355(11):1124-1140 (Pubitemid 44394919)
4. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L (2009) Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72(1):73-79
5. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel- Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402-415
6. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L (2010) Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 16(2):197-207
7. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401
8. Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354(9):942-955
9. Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 5(3):529-536 (Pubitemid 40313344)
10. Brinkmann V, Baumruker T (2006) Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 6(3):244-250 (Pubitemid 44274746)
11. Kume H, Takeda N, Oguma T, Ito S, Kondo M, Ito Y, Shimokata K (2007) Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation. J Pharmacol Exp Ther 320(2):766-773 (Pubitemid 46147958)
12. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G (2004) Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 57 (5):586-591 (Pubitemid 38582178)
13. Schmouder R, Serra D, Wang Y, Kovarik JM, DiMarco J, Hunt TL, Bastien MC (2006) FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 46(8):895-904 (Pubitemid 44050826)
14. Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, Schmouder RL (2007) Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos 28(2):97-104 (Pubitemid 46455770)
15. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71(16):1261-1267
16. Hofmann M, Brinkmann V, Zerwes HG (2006) FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 6(13-14):1902-1910 (Pubitemid 44855701)
17. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM (2000) FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 164(11):5761-5770 (Pubitemid 30389819)